Preliminary Single-Center Experience with the Bolton Treovance Endograft in the Treatment of Abdominal Aortic Aneurysms.
Our aim was to present our preliminary experience with the recently introduced Treovance aortic stent-graft device (Bolton Medical, Barcelona, Spain) in the treatment of abdominal aortic aneurysm (AAA). Eight patients underwent treatment of an infrarenal AAA (mean maximum diameter, 56.4 ± 6.8 mm) with the Treovance device. Iliac tortuosity was considered mild, moderate, or severe when ≥1 angulation of 45-90°, 1 angulation ≥90°, or ≥2 angulations ≥90°, respectively, were present. Mild angulation of the infrarenal neck (10-45°) was present in 7 patients, whereas the remaining patient had severe infrarenal neck angulation (65°). Three patients had severe iliac tortuosity. Primary technical success was achieved in all but 1 patient in whom a type Ia endoleak was identified on completion angiogram. The endoleak was successfully treated with a proximal aortic cuff. A femoral access complication occurred in 1 patient. Mean follow-up was 6.8 months (range, 1-12). No device-related serious adverse events or rupture occurred during the given follow-up period. The only type II endoleak identified resolved spontaneously within 12 months. The Treovance abdominal stent-graft system seems to guarantee an accurate, safe, and effective deployment in AAA even through angulated and tortuous iliac vessels. Although our preliminary results are promising, follow-up data are needed to establish the durability of this new-generation endovascular device in standard or challenging anatomies.